Spyre Therapeutics initiated with early-stage designation at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated Spyre Therapeutics (SYRE) with an early-stage biotech designation. The firm sees an “attractive mix of clinically validated targets” and long-acting antibody technology that could potentially upend the inflammatory bowel disease and broader autoimmune treatment landscape. If one of the Spyre co-formulated program reach the Phase 2 topline stage and show a treatment effect size similar to the VEGA study, the potential value inflection could be significant, the analyst tells investors in a research note.